TWI350170B - Treating agent for glaucoma comprising rho kinase inhibitor and prostaglandin - Google Patents
Treating agent for glaucoma comprising rho kinase inhibitor and prostaglandinInfo
- Publication number
- TWI350170B TWI350170B TW099103157A TW99103157A TWI350170B TW I350170 B TWI350170 B TW I350170B TW 099103157 A TW099103157 A TW 099103157A TW 99103157 A TW99103157 A TW 99103157A TW I350170 B TWI350170 B TW I350170B
- Authority
- TW
- Taiwan
- Prior art keywords
- kinase inhibitor
- rho kinase
- glaucoma
- prostaglandin
- treating agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002250223 | 2002-08-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201032807A TW201032807A (en) | 2010-09-16 |
TWI350170B true TWI350170B (en) | 2011-10-11 |
Family
ID=31972618
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW092123857A TWI337881B (en) | 2002-08-29 | 2003-08-29 | Treating agent for glaucoma comprising rho kinase inhibitor and prostaglandin |
TW099103157A TWI350170B (en) | 2002-08-29 | 2003-08-29 | Treating agent for glaucoma comprising rho kinase inhibitor and prostaglandin |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW092123857A TWI337881B (en) | 2002-08-29 | 2003-08-29 | Treating agent for glaucoma comprising rho kinase inhibitor and prostaglandin |
Country Status (11)
Country | Link |
---|---|
US (4) | US20050245509A1 (zh) |
EP (2) | EP2314299A1 (zh) |
JP (1) | JP5174777B2 (zh) |
KR (2) | KR101160780B1 (zh) |
CN (1) | CN100425241C (zh) |
AT (1) | ATE546143T1 (zh) |
AU (1) | AU2003257588A1 (zh) |
CA (1) | CA2496797C (zh) |
ES (1) | ES2382733T3 (zh) |
TW (2) | TWI337881B (zh) |
WO (1) | WO2004019951A1 (zh) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050245509A1 (en) * | 2002-08-29 | 2005-11-03 | Santen Pharmacecutical Co., Ltd. | Remedy for glaucoma comprising rho kinase inhibitor and prostaglandins |
WO2004045644A1 (ja) * | 2002-11-18 | 2004-06-03 | Santen Pharmaceutical Co., Ltd. | Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤 |
US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
US8673341B2 (en) | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
KR101333970B1 (ko) * | 2005-05-19 | 2013-11-27 | 코와 가부시키가이샤 | 녹내장 예방 또는 치료제 |
US8629161B2 (en) * | 2005-06-21 | 2014-01-14 | Kowa Co., Ltd. | Preventive or remedy for glaucoma |
US8193193B2 (en) | 2005-07-12 | 2012-06-05 | Kowa Co., Ltd. | Agent for prevention or treatment of glaucoma |
EP1932841B1 (en) * | 2005-08-30 | 2014-01-01 | Asahi Kasei Pharma Corporation | Sulfonamide compound |
JP2009513660A (ja) * | 2005-10-26 | 2009-04-02 | 旭化成ファーマ株式会社 | 肺動脈性高血圧の治療用併用療法におけるファスジル |
JP5235887B2 (ja) | 2006-09-20 | 2013-07-10 | アエリー ファーマシューティカルズ インコーポレイテッド | Rhoキナーゼ阻害剤 |
US8071779B2 (en) * | 2006-12-18 | 2011-12-06 | Inspire Pharmaceuticals, Inc. | Cytoskeletal active rho kinase inhibitor compounds, composition and use |
US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
WO2008105058A1 (ja) | 2007-02-27 | 2008-09-04 | Asahi Kasei Pharma Corporation | スルホンアミド化合物 |
WO2008105442A1 (ja) | 2007-02-28 | 2008-09-04 | Asahi Kasei Pharma Corporation | スルホンアミド誘導体 |
CN101313926B (zh) * | 2007-05-30 | 2012-12-26 | 中央研究院 | 转录调控物组合物 |
AU2008272396B2 (en) | 2007-07-02 | 2011-09-08 | Asahi Kasei Pharma Corporation | Sulfonamide Compound and Crystal Thereof |
US8207195B2 (en) | 2008-06-26 | 2012-06-26 | Inspire Pharmaceuticals, Inc. | Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds |
US8410147B2 (en) | 2008-06-26 | 2013-04-02 | Inspire Pharmaceuticals, Inc. | Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds |
US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
EP3354643B1 (en) | 2009-05-01 | 2020-10-28 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
BR112013001125A2 (pt) * | 2010-07-19 | 2016-05-17 | Inspire Pharmaceuticals Inc | compostos inibidores de rho cinase bifuncionais, composição e uso |
WO2012043891A1 (ja) | 2010-09-30 | 2012-04-05 | ダイトーケミックス株式会社 | 眼疾患処置薬 |
TW202126308A (zh) * | 2011-02-04 | 2021-07-16 | 日商興和股份有限公司 | 青光眼治療劑與高眼壓症治療劑 |
KR102074020B1 (ko) * | 2012-07-13 | 2020-02-05 | 산텐 세이야꾸 가부시키가이샤 | 술폰아미드 화합물의 조합 |
US9339496B2 (en) | 2012-07-13 | 2016-05-17 | Santen Pharmaceutical Co., Ltd. | Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist |
HUE061618T2 (hu) * | 2013-03-15 | 2023-07-28 | Aerie Pharmaceuticals Inc | Vegyület szemrendellenességek kezelésére |
EP4406535A3 (en) | 2013-10-31 | 2024-11-06 | Allergan, Inc. | Prostamide-containing intraocular implants and methods of use thereof |
KR20150090445A (ko) | 2014-01-29 | 2015-08-06 | 주식회사 이노칩테크놀로지 | 적층칩 소자 |
MY178880A (en) * | 2014-12-12 | 2020-10-21 | Kowa Co | Composition |
KR20180021741A (ko) * | 2015-05-29 | 2018-03-05 | 에쥐 세라피틱스, 인코포레이티드 | 시각 손실을 감소시키기 위한 조성물 및 방법 |
KR102579582B1 (ko) | 2015-11-17 | 2023-09-15 | 에어리 파마슈티컬즈, 인코포레이티드 | 키나아제 억제제 및 이의 중간체의 제조 방법 |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
MX2019002396A (es) | 2016-08-31 | 2019-07-08 | Aerie Pharmaceuticals Inc | Composiciones oftalmicas. |
CA3057872A1 (en) | 2017-03-31 | 2018-10-04 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
TWI833535B (zh) | 2017-12-21 | 2024-02-21 | 日商參天製藥股份有限公司 | 賽佩普斯特(Sepetaprost)及Rho激酶抑制劑之組合醫藥 |
CA3086445A1 (en) | 2017-12-21 | 2019-06-27 | Santen Pharmaceutical Co., Ltd. | Omidenepag combination |
US10696638B2 (en) | 2017-12-26 | 2020-06-30 | Industrial Technology Research Institute | Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same |
CN108815169A (zh) * | 2018-05-23 | 2018-11-16 | 中南大学湘雅医院 | 一种前列腺素类物质组合得到有效的青光眼治疗剂 |
AU2019337703B2 (en) | 2018-09-14 | 2023-02-02 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
JPWO2021182596A1 (zh) * | 2020-03-13 | 2021-09-16 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2945008C2 (de) * | 1979-11-08 | 1981-08-20 | Lück, Werner, 4290 Bocholt | Stützelement für medizinische Lagerungszwecke |
US4599353A (en) * | 1982-05-03 | 1986-07-08 | The Trustees Of Columbia University In The City Of New York | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma |
US4952581A (en) * | 1987-04-03 | 1990-08-28 | The Trustees Of Columbia University In The City Of New York | Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure |
ATE76750T1 (de) * | 1987-04-03 | 1992-06-15 | Univ Columbia | Anwendung eines prostaglandins in mischung mit einem adrenergischen blocker zur verminderung des augen-innendruckes. |
CA1324129C (en) * | 1987-04-30 | 1993-11-09 | Ryuzo Ueno | Prostaglandins of the f series |
ATE82499T1 (de) | 1987-09-18 | 1992-12-15 | R Tech Ueno Ltd | Okulare hypotensivagenzien. |
CA1334168C (en) * | 1988-04-26 | 1995-01-31 | Louis M. De Santis | Antiglaucoma compositions containing combinations of .alpha.-2 agonists and .beta. blockers |
JPH02108U (zh) | 1988-06-14 | 1990-01-05 | ||
ES2193901T1 (es) * | 1988-09-06 | 2003-11-16 | Pharmacia Ab | Derivados de prostaglandina para el tratamiento de glaucoma o hipertension ocular. |
US5352708A (en) | 1992-09-21 | 1994-10-04 | Allergan, Inc. | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
US5510383A (en) * | 1993-08-03 | 1996-04-23 | Alcon Laboratories, Inc. | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
CN1155383C (zh) * | 1995-12-21 | 2004-06-30 | 阿尔康实验室公司 | 某些异喹啉磺酰基化合物治疗青光眼及眼局部缺血的用途 |
BR9711154A (pt) * | 1996-08-12 | 1999-08-17 | Yoshitomi Pharmaceutical | Agente farmac-utico contendo inibidor cinase rho |
EP1702623B1 (en) * | 1998-04-02 | 2008-10-08 | Genentech, Inc. | Use of interferon gamma for the treatment of cardiac hypertrophy |
JP4212149B2 (ja) | 1998-06-11 | 2009-01-21 | 株式会社デ・ウエスタン・セラピテクス研究所 | 医薬 |
ATE527993T1 (de) * | 1998-08-17 | 2011-10-15 | Senju Pharma Co | Verbindung zur vorbeugung und behandlung von augen-asthenopie und pseudomyopie |
SE9803761D0 (sv) * | 1998-11-04 | 1998-11-04 | Synphora Ab | Method to avoid increased iridial pigmentation during prostaglandin treatment |
AU3328600A (en) * | 1999-03-25 | 2000-10-16 | Santen Pharmaceutical Co. Ltd. | Ocular tension-lowering agents |
US7217722B2 (en) | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
AR035541A1 (es) | 2000-11-13 | 2004-06-16 | Pharmacia Ab | Un metodo de tratamiento para pacientes que sufren de glaucoma severo o necesitan una reduccion de la presion intraocular (pio) y el uso de una combinacion de agentes reductores de la pio |
US20030087919A1 (en) | 2001-03-23 | 2003-05-08 | Bayer Corporation | Rho-kinase inhibitors |
PT1370553E (pt) | 2001-03-23 | 2006-09-29 | Bayer Corp | Inibidores de rhoquinase |
WO2002100833A1 (fr) | 2001-06-12 | 2002-12-19 | Sumitomo Pharmaceuticals Company, Limited | Inhibiteurs de rho kinase |
CN1774251A (zh) * | 2001-12-12 | 2006-05-17 | 法玛西雅公司 | 应用环氧甾类醛固酮受体拮抗剂治疗眼病的方法 |
US20050245509A1 (en) * | 2002-08-29 | 2005-11-03 | Santen Pharmacecutical Co., Ltd. | Remedy for glaucoma comprising rho kinase inhibitor and prostaglandins |
WO2004045644A1 (ja) * | 2002-11-18 | 2004-06-03 | Santen Pharmaceutical Co., Ltd. | Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤 |
US20050014783A1 (en) * | 2003-05-29 | 2005-01-20 | Schering Aktiengesellschaft | Use of Rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy |
-
2003
- 2003-08-29 US US10/525,986 patent/US20050245509A1/en not_active Abandoned
- 2003-08-29 CA CA2496797A patent/CA2496797C/en not_active Expired - Fee Related
- 2003-08-29 KR KR1020107029307A patent/KR101160780B1/ko active IP Right Grant
- 2003-08-29 WO PCT/JP2003/011004 patent/WO2004019951A1/ja active Application Filing
- 2003-08-29 TW TW092123857A patent/TWI337881B/zh not_active IP Right Cessation
- 2003-08-29 CN CNB038233029A patent/CN100425241C/zh not_active Expired - Fee Related
- 2003-08-29 TW TW099103157A patent/TWI350170B/zh not_active IP Right Cessation
- 2003-08-29 EP EP10192265A patent/EP2314299A1/en not_active Withdrawn
- 2003-08-29 EP EP03791404A patent/EP1541151B1/en not_active Expired - Lifetime
- 2003-08-29 AT AT03791404T patent/ATE546143T1/de active
- 2003-08-29 ES ES03791404T patent/ES2382733T3/es not_active Expired - Lifetime
- 2003-08-29 AU AU2003257588A patent/AU2003257588A1/en not_active Abandoned
- 2003-08-29 KR KR1020057003416A patent/KR101092048B1/ko not_active IP Right Cessation
-
2009
- 2009-09-25 JP JP2009220230A patent/JP5174777B2/ja not_active Expired - Fee Related
- 2009-10-16 US US12/589,004 patent/US20100063060A1/en not_active Abandoned
- 2009-10-16 US US12/589,073 patent/US20100041671A1/en not_active Abandoned
-
2011
- 2011-10-25 US US13/280,684 patent/US20120040994A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2004019951A1 (ja) | 2004-03-11 |
US20050245509A1 (en) | 2005-11-03 |
CA2496797A1 (en) | 2004-03-11 |
CA2496797C (en) | 2012-01-10 |
TWI337881B (en) | 2011-03-01 |
KR101092048B1 (ko) | 2011-12-12 |
CN100425241C (zh) | 2008-10-15 |
CN1684689A (zh) | 2005-10-19 |
EP1541151A1 (en) | 2005-06-15 |
EP1541151B1 (en) | 2012-02-22 |
EP1541151A4 (en) | 2007-07-18 |
KR20050057014A (ko) | 2005-06-16 |
KR20110004920A (ko) | 2011-01-14 |
ATE546143T1 (de) | 2012-03-15 |
ES2382733T3 (es) | 2012-06-13 |
AU2003257588A1 (en) | 2004-03-19 |
US20100063060A1 (en) | 2010-03-11 |
TW201032807A (en) | 2010-09-16 |
JP2009298808A (ja) | 2009-12-24 |
EP2314299A1 (en) | 2011-04-27 |
TW200409654A (en) | 2004-06-16 |
KR101160780B1 (ko) | 2012-06-27 |
US20120040994A1 (en) | 2012-02-16 |
JP5174777B2 (ja) | 2013-04-03 |
US20100041671A1 (en) | 2010-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI350170B (en) | Treating agent for glaucoma comprising rho kinase inhibitor and prostaglandin | |
SE0202462D0 (sv) | Novel use | |
EP1248612A4 (en) | NEW SUBSTANCES AND COMPOUNDS AS PROTEASE INHIBITORS | |
SE0202429D0 (sv) | Novel Compounds | |
BRPI0418245B8 (pt) | composto derivado de nitróxi de prostaglandina, processo para preparar dito composto, composição farmacêutica compreendendo dito composto e usos destes | |
IL178122A0 (en) | Materials and methods for treating coagulation disorders | |
TW200626558A (en) | Indazolone derivatives | |
MY147643A (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder | |
CA2454976A1 (en) | Therapeutic agent for glaucoma comprising compound having pi3 kinase inhibitory action as active ingredient | |
WO2003072066A3 (en) | Compositions and methods for the treatment of glaucoma and ocular hypertension | |
RU2008127882A (ru) | Лечение пищевода барретта | |
TW200621765A (en) | Substituted phenylaminothiazoles and their use | |
MX2021013942A (es) | Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton. | |
AU2020278236A8 (en) | Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor | |
TW200602035A (en) | [4-(5-Aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase | |
AR061233A1 (es) | Formulacion de liberacion prolongada de naltrexona | |
MY133107A (en) | Use of pyrimidine derivatives for the prophylaxis and therapy of cerebral ischemia | |
EA200601418A1 (ru) | ПРОИЗВОДНЫЕ 1Н-ТИЕНО [2,3-с] ПИРАЗОЛА, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ИСПОЛЬЗОВАНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ | |
MX2022003845A (es) | Tratamientos cognitivos medicinales. | |
MX2007011814A (es) | Compuestos citoesqueleticos activos, composiciones y usos. | |
HRP20080255A2 (en) | Use of cicletanine and other furopyridines for treatment of systolic predominant hypertension, isolated systolic hypertension, elevated pulse pressure and general hypertension | |
TW200503709A (en) | Itching treating agent containing piperidine derivative as active ingredient | |
SE0002211D0 (sv) | Methods and compositions for prevention of myopia | |
IS6555A (is) | Meðferð með aðskildum skömmtum sem hafa æðaskaðandi virkni | |
BR0209601A (pt) | Método para o tratamento da hipertensão ocular e do glaucoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |